NASDAQ · BEAM
Healthcare · Biotechnology
$23.22
Down-$0.90 (-3.73%)
Updated Sep 16, 2026, 1:27 PM
SID Score
4.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BEAM closed at $23.22 after 20 trading sessions, down 12.61% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $23.82 | $23.84 | $22.86 | $23.22 | 2.58M |
| Sep 14, 2026 | $24.02 | $24.9299 | $23.99 | $24.12 | 1.46M |
| Sep 11, 2026 | $24.64 | $24.7599 | $23.95 | $23.99 | 1.19M |
| Sep 10, 2026 | $24.76 | $24.89 | $23.98 | $24.37 | 1.98M |
| Sep 9, 2026 | $26.70 | $26.70 | $25.11 | $25.175 | 2.85M |
| Sep 8, 2026 | $26.76 | $27.30 | $25.035 | $26.83 | 6.18M |
| Sep 4, 2026 | $28.91 | $29.97 | $28.91 | $29.66 | 1.18M |
| Sep 3, 2026 | $29.49 | $29.65 | $28.02 | $29.46 | 1.27M |
| Sep 2, 2026 | $29.27 | $30.1776 | $28.23 | $29.29 | 1.29M |
| Sep 1, 2026 | $28.82 | $29.5588 | $28.70 | $29.02 | 889.44K |
| Aug 31, 2026 | $28.82 | $29.82 | $28.33 | $29.43 | 1.31M |
| Aug 28, 2026 | $29.527 | $30.50 | $29.01 | $29.32 | 1.33M |
| Aug 27, 2026 | $30.14 | $30.82 | $29.72 | $30.48 | 1.27M |
| Aug 26, 2026 | $30.96 | $31.015 | $29.76 | $30.19 | 1.39M |
| Aug 25, 2026 | $28.94 | $31.48 | $28.78 | $31.03 | 2.19M |
| Aug 24, 2026 | $29.25 | $29.35 | $28.23 | $28.33 | 1.25M |
| Aug 21, 2026 | $28.74 | $30.50 | $28.61 | $29.76 | 2.46M |
| Aug 20, 2026 | $28.08 | $29.10 | $26.98 | $28.39 | 2.41M |
| Aug 19, 2026 | $28.41 | $29.16 | $27.64 | $29.07 | 3.11M |
| Aug 18, 2026 | $26.18 | $26.93 | $26.00 | $26.57 | 1.2M |
The latest Smart Investors Daily articles mentioning BEAM.
BEAM research
Company profile and research snapshot.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Wedbush | Outperform | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 8, 2026 | B of A Securities | Buy | — |
| Jul 7, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Bernstein | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 11, 2026
Beam Therapeutics' BEAM-302 Phase 1/2 AATD results show sustained AAT increases, but durability, safety, and approval risks remain. Click for this BEAM update
Yahoo · Sep 10, 2026
Beam Therapeutics Inc. (NASDAQ:BEAM) reported updated Phase 1/2 results on September 8 for BEAM-302, an investigational gene-editing treatment for alpha-1 antitrypsin deficiency, or AATD. Although 38 patients had been treated by August 17, the presented efficacy analysis covered 29 single-dose patients at the June 24 cutoff. Biomarker results extended to 18 months, while overall patient […]
SeekingAlpha · Sep 10, 2026
2026-09-10. The following slide deck was published by Beam Therapeutics Inc.
SeekingAlpha · Sep 10, 2026
2026-09-10. The following slide deck was published by Beam Therapeutics Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BEAM.
